PJC Piper Jaffray Companies

LONDON, June 19 /PRNewswire-FirstCall/ -- Piper Jaffray Ltd. is pleased to announce it is holding its first London Health Care Conference June 22-23 in the United Kingdom. The conference will feature presentations by management teams in the biopharmaceutical and medical technology industries from both Europe and the United States. Presentations will last approximately 20 minutes. "We are delighted to be hosting our first health care conference in the UK," said David Wilson, chief executive officer of Piper Jaffray Ltd. "The conference includes a very strong line-up of leading biopharmaceutical and medical technology companies that will provide clients updated insight on current and new trends in the industry." Piper Jaffray will also be hosting its 18th annual U.S. Health Care Conference November 29-December 1 in New York. Companies scheduled to present and attend the London Health Care Conference include: Acambis Plc, Actelion Ltd., Alizyme Plc, Allergy Therapeutics Ltd., Alliance Pharma Plc, Amylin Pharmaceuticals, Inc., Anadys Pharmaceuticals, Inc., Antisoma Plc, Ardana Plc, Ark Therapeutics Group Plc, Arpida Ag, ArthroCare Corporation, Asterand Plc, Axis-Shield Plc, Basilea Pharmaceutica Ltd., Bespak Plc, BioAlliance Pharma, Biocompatibles International Plc, BTG Plc, Celgene Corporation, CeNeS Pharmaceuticals Plc, Corin Group Plc, Crucell NV, Cubist Pharmaceuticals Inc., CuraGen Corporation, Evolutec Group Plc, Evotec AG, Exelixis, Inc., Exonhit Therapeutics SA, Galapagos nv, Genetix Group Plc, Genmab A/S, GPC Biotech AG, Gyrus Group Plc, Huntleigh Technology Plc, Immucor, Inc., Inion Oy, Innogenetics NV, Innovata Plc, Integra LifeSciences Holdings Corporation, Intercytex Group Plc, Jerini AG, Kyphon Inc., MannKind Corporation, Micromet, Inc., NeuroSearch A/S, NicOx SA, Osmetech Plc, Oxford BioMedica Plc, Pharmexa A/S, Plethora Solutions, ProStraken, Protherics Plc, Qiagen, SGX Pharmaceuticals, Inc., Sinclair Pharmaceuticals, SkyePharma Plc, Smith & Nephew plc, SpaceLabs Healthcare, Speedel Pharmaceuticals Inc., Tissue Science Laboratories plc, TopoTarget A/S, Vectura Group Plc, Vernalis Plc, Vertex Pharmaceuticals Inc., Vical Incorporated, Vital Signs Inc., Wright Medical Group, Inc. Company and investor participation in the Piper Jaffray London Health Care Conference is by invitation only. Clients interested in attending should contact their Piper Jaffray representative. Piper Jaffray Companies (NYSE:PJC) is a focused securities firm dedicated to delivering superior financial advice, investment products and transaction execution within selected sectors of the financial services marketplace. The company currently operates through two primary revenue-generating segments: Capital Markets and Private Client Services. The sale of the company's Private Client Services branch network, announced April 11, 2006, currently is pending. The company's Capital Markets business generates revenue through two groups: Corporate and Institutional Services and Public Finance Services. Through its chief operating subsidiary in the U.S., Piper Jaffray & Co., the firm has served corporations, government and non-profit entities, institutional investors and the financial advisory needs of private individuals since 1895. With headquarters in Minneapolis, Piper Jaffray currently has approximately 2,800 employees in 107 offices in 23 states across the country and in London. The firm's UK operating subsidiary, Piper Jaffray Ltd., is authorized and regulated by the Financial Services Authority and is a member of the London Stock Exchange. For more information about Piper Jaffray, visit us online at http://www.piperjaffray.com/ . Since 1895. Member SIPC and NYSE. SOURCE Piper Jaffray Ltd. CONTACT: Rob Litt of Piper Jaffray Ltd., +1-612-303-8266, Web site: http://www.piperjaffray.com/

Copyright